NASDAQ:BCAB BioAtla (BCAB) Stock Price, News & Analysis $1.85 -0.11 (-5.61%) (As of 10/17/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About BioAtla Stock (NASDAQ:BCAB) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get BioAtla alerts:Sign Up Key Stats Today's Range$1.84▼$1.9950-Day Range$1.39▼$2.3552-Week Range$1.14▼$4.02Volume765,164 shsAverage Volume836,714 shsMarket Capitalization$89.01 millionP/E RatioN/ADividend YieldN/APrice Target$6.00Consensus RatingBuy Company OverviewBioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody, which is in Phase II clinical trial for treating melanoma, carcinomas, and NSCLC; and BA3182, a bispecific candidate that is in Phase 1 study for the treatment of adenocarcinomas, as well as BA3361, which is in preclinical studies for treating multiple tumor types. The company was founded in 2007 and is headquartered in San Diego, California.Read More… [Urgent] Starlink Set For The Largest IPO In History? (Ad)He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again with Tesla… which is up more than 19,500% since 2010. For perspective, that turns $100 invested into almost $20,000! And now, Elon could be set to do it for the third and final time… with what might be his biggest breakthrough yet. And for the first time ever, you have the rare chance to profit BEFORE the upcoming IPO.Click here now for the urgent details on this hidden play. BioAtla Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks49th Percentile Overall ScoreBCAB MarketRank™: BioAtla scored higher than 49% of companies evaluated by MarketBeat, and ranked 594th out of 1,012 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingBioAtla has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageBioAtla has only been the subject of 1 research reports in the past 90 days.Read more about BioAtla's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for BioAtla are expected to decrease in the coming year, from ($1.52) to ($1.74) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BioAtla is -0.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BioAtla is -0.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBioAtla has a P/B Ratio of 1.26. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about BioAtla's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted9.29% of the outstanding shares of BioAtla have been sold short.Short Interest Ratio / Days to CoverBioAtla has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in BioAtla has recently increased by 0.45%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBioAtla does not currently pay a dividend.Dividend GrowthBioAtla does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted9.29% of the outstanding shares of BioAtla have been sold short.Short Interest Ratio / Days to CoverBioAtla has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in BioAtla has recently increased by 0.45%, indicating that investor sentiment is decreasing. News and Social Media2.6 / 5News Sentiment0.75 News SentimentBioAtla has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for BioAtla this week, compared to 1 article on an average week.Search InterestOnly 4 people have searched for BCAB on MarketBeat in the last 30 days. This is a decrease of -56% compared to the previous 30 days.MarketBeat Follows6 people have added BioAtla to their MarketBeat watchlist in the last 30 days. This is an increase of 500% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, BioAtla insiders have not sold or bought any company stock.Percentage Held by Insiders11.50% of the stock of BioAtla is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions77.23% of the stock of BioAtla is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about BioAtla's insider trading history. Receive BCAB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioAtla and its competitors with MarketBeat's FREE daily newsletter. Email Address BCAB Stock News HeadlinesHead-To-Head Review: Calidi Biotherapeutics (NYSE:CLDI) & BioAtla (NASDAQ:BCAB)October 16 at 2:17 AM | americanbankingnews.comBioAtla Inc (BCAB) Q2 2024 Earnings Call Highlights: Strategic Progress Amid Financial ChallengesOctober 10, 2024 | finance.yahoo.com[Urgent] Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again with Tesla… which is up more than 19,500% since 2010. For perspective, that turns $100 invested into almost $20,000! And now, Elon could be set to do it for the third and final time… with what might be his biggest breakthrough yet. And for the first time ever, you have the rare chance to profit BEFORE the upcoming IPO.October 17, 2024 | Paradigm Press (Ad)BioAtla's FDA Fast-Tracked Drug Candidate Boosts Its Oncology Prospects, Speculative BuyOctober 8, 2024 | seekingalpha.comBioAtla: Numerous Catalysts Coming In Q4October 7, 2024 | seekingalpha.comBioAtla Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual MeetingOctober 4, 2024 | globenewswire.comBioAtla Announces Upcoming Oral Presentation at the Society for Melanoma Research 21st International CongressOctober 1, 2024 | markets.businessinsider.comBioAtla Announces Upcoming Oral Presentation at the Society for Melanoma Research 21st International CongressOctober 1, 2024 | globenewswire.comSee More Headlines BCAB Stock Analysis - Frequently Asked Questions How have BCAB shares performed this year? BioAtla's stock was trading at $2.46 on January 1st, 2024. Since then, BCAB stock has decreased by 24.8% and is now trading at $1.85. View the best growth stocks for 2024 here. How were BioAtla's earnings last quarter? BioAtla, Inc. (NASDAQ:BCAB) issued its earnings results on Thursday, August, 8th. The company reported ($0.44) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.45) by $0.01. When did BioAtla IPO? BioAtla (BCAB) raised $150 million in an initial public offering on Wednesday, December 16th 2020. The company issued 9,400,000 shares at $15.00-$17.00 per share. J.P. Morgan, Jefferies, Credit Suisse and BTIG served as the underwriters for the IPO. Who are BioAtla's major shareholders? BioAtla's top institutional shareholders include Vontobel Holding Ltd. (0.03%). Insiders that own company stock include Jay M Phd Short, Christian Vasquez, Lawrence Steinman, Sylvia Mcbrinn, Richard A Waldron and Scott Andrew Smith. View institutional ownership trends. How do I buy shares of BioAtla? Shares of BCAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of BioAtla own? Based on aggregate information from My MarketBeat watchlists, some other companies that BioAtla investors own include NVIDIA (NVDA), Tesla (TSLA), Meta Platforms (META), JPMorgan Chase & Co. (JPM), Advanced Micro Devices (AMD), Netflix (NFLX) and Visa (V). Company Calendar Last Earnings8/08/2024Today10/17/2024Next Earnings (Estimated)11/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:BCAB CUSIPN/A CIK1826892 Webwww.bioatla.com Phone858-558-0708FaxN/AEmployees60Year FoundedN/APrice Target and Rating Average Stock Price Target$6.00 High Stock Price Target$7.00 Low Stock Price Target$5.00 Potential Upside/Downside+224.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($2.49) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-123,460,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-169.69% Return on Assets-97.52% Debt Debt-to-Equity RatioN/A Current Ratio3.81 Quick Ratio3.81 Sales & Book Value Annual Sales$250,000.00 Price / Sales356.06 Cash FlowN/A Price / Cash FlowN/A Book Value$1.47 per share Price / Book1.26Miscellaneous Outstanding Shares48,116,000Free Float42,777,000Market Cap$89.01 million OptionableOptionable Beta1.06 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report This page (NASDAQ:BCAB) was last updated on 10/17/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredRetire off just one stock ticker?ONE AI Stock is All You Need... There are over 6,000 stocks listed in the market right now. They will NOT m...Behind the Markets | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredAdd $2T of Potential Magic to Your PortfolioRevolutionizing a whole $2T entertainment and licensing industry might sound like the stuff of fairytales. But...Elf Labs | SponsoredEquation for Profits: Volatility = OpportunityFREE Intro to Options Class Online Tonight Prosper Trading Academy | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioAtla, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioAtla With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free bcab Stock Alerts